KMT2A and acute lymphoblastic leukemia: In aggregate, we wish to highlight the therapeutic potential of CSPG4-CAR T cells as a possible back-up modality for B-ALL relapsing to CD19-CAR T cell therapy, with special emphasis on MLL leukemias, which harbor the potential to undergo a lineage switch and shed all B cell-associated antigens.